



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

Ref:PR/10/2014

Press Release

Breckenridge/NATCO files ANDA for Everolimus, 0.25mg, 0.5mg, and 0.75mg Tablets

Hyderabad, India, September 5th, 2014

Natco Pharma Limited (NSE: NATCOPHARM) announced today that its marketing partner in the USA, Breckenridge Pharmaceutical, Inc. (BPI), has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets.

Natco and BPI believe that its Paragraph IV ANDA was filed on the First-to-File date and expects to be the only generic that is entitled to the 180-day exclusivity period.

Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress® in the USA market. Zortress® is used to prevent organ rejection after a kidney or liver transplant. Zortress® generated sales of \$43.5 million for the twelve-month period ending July 2014, based on industry sales data.

Zortress® is a trademark of Novartis AG or its affiliates.

Forwarded for favor of publication

For NATCO Pharma Limited

M Adinarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)